Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions
Tuesday, March 12, 2024AbCellera and Biogen Inc have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Monday, March 11, 2024Mesoblast Limited global leader in allogeneic cellular medicines for inflammatory
TransThera Announces Phase 3 Trial for Cholangiocarcinoma in EU & Orphan Drug Designation for Tinengotinib
Saturday, March 09, 2024TransThera a clinicalstage biopharmaceutical company dedicated to innovating differentiated drugs globally today announced that the randomized controlled global multicenter Phase trial of tinengotinib
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
Saturday, March 09, 2024Arrowhead Pharmaceuticals Inc announced today that it has dosed the first subjects in a Phase a doubleblinded placebocontrolled doseescalating study to evaluate single and multiple ascending doses
Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis
Friday, March 08, 2024Kyverna Therapeutics Inc a patientcentered clinicalstage biopharmaceutical company focused on developing cell therapies for patients suffering
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma
Friday, March 08, 2024BeiGene Ltd a global oncology company today announced that the US Food and Drug Administration has granted accelerated approval to BRUKINSA
Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
Thursday, March 07, 2024Tonix Pharmaceuticals Holding Corp a biopharmaceutical company with marketed products and a pipeline of development candidates announced today that
Johnson & Johnson Applies for DARZALEX®-Based Therapy for Newly Diagnosed Multiple Myeloma in Europe
Thursday, March 07, 2024JanssenCilag International NV a Johnson Johnson company today announced the submission of a Type II variation application to the European Medicines Agency The submission is seeking approval for an indication extension
LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
Wednesday, March 06, 2024LAVA Therapeutics NV a clinicalstage immunooncology company focused on developing its proprietary Gammabody platform of bispecific gamma delta T cell engagers today announced that Pfizer
Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma
Wednesday, March 06, 2024Innate Pharma SA today announced the first patient was dosed in its Phase multicenter trial investigating the safety and tolerability of IPH in patients with
